Use of bisphosphonates in the management of postmenopausal osteoporosis

被引:22
作者
Papapoulos, Socrates E. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Endocrinol & Metab Dis, NL-2333 ZA Leiden, Netherlands
来源
BISPHOSPHONATES AND OSTEONECROSIS OF THE JAW | 2011年 / 1218卷
关键词
bisphosphonates; bone remodeling; fractures; osteoporosis; BONE-MINERAL DENSITY; MONTHLY ORAL IBANDRONATE; VERTEBRAL FRACTURE RISK; INTRAVENOUS ZOLEDRONIC ACID; LONG-TERM RISEDRONATE; MICRODAMAGE ACCUMULATION; NONVERTEBRAL FRACTURES; BIOMECHANICAL PROPERTIES; ETIDRONATE TREATMENT; CLINICAL FRACTURES;
D O I
10.1111/j.1749-6632.2010.05767.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonates are widely used in the treatment of postmenopausal osteoporosis. They decrease the rate of bone turnover, maintain or improve structural and material properties of bone, and increase bone mineral density and thereby decrease the risk of fractures. Available potent bisphosphonates can be given to patients by different dosing regimens that range from daily oral administration to yearly intravenous infusions. Controlled studies, extending to 10 years of continuous treatment, provide information about long-term efficacy and safety and can help in the planning of long-term treatment strategies. Selection of bisphosphonates for the treatment of individuals should be based on a careful review of efficacy data, a risk profile of the bisphosphonate, and values and preferences of the patient.
引用
收藏
页码:15 / 32
页数:18
相关论文
共 118 条
  • [1] Adverse Effects of Bisphosphonates
    Abrahamsen, Bo
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) : 421 - 435
  • [2] Adachi JD, 2005, AGING CLIN EXP RES, V17, P150
  • [3] Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
    Allen, Matthew R.
    Iwata, Ken
    Phipps, Roger
    Burr, David B.
    [J]. BONE, 2006, 39 (04) : 872 - 879
  • [4] [Anonymous], 1993, Am J Med, V95, p1S
  • [5] Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal
    Bagger, YZ
    Tankó, LB
    Alexandersen, P
    Ravn, P
    Christiansen, C
    [J]. BONE, 2003, 33 (03) : 301 - 307
  • [6] Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
    Bauer, DC
    Black, DM
    Garnero, P
    Hochberg, M
    Ott, S
    Orloff, J
    Thompson, DE
    Ewing, SK
    Delmas, PD
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1250 - 1258
  • [7] BILEZIKIAN J, 2009, J BONE MINER RES S1, V24
  • [8] Osteonecrosis of the jaw - Do biphosphonates pose a risk?
    Bilezikian, John P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2278 - 2281
  • [9] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
    Black, Dennis M.
    Delmas, Pierre D.
    Eastell, Richard
    Reid, Ian R.
    Boonen, Steven
    Cauley, Jane A.
    Cosman, Felicia
    Lakatos, Peter
    Leung, Ping Chung
    Man, Zulema
    Mautalen, Carlos
    Mesenbrink, Peter
    Hu, Huilin
    Caminis, John
    Tong, Karen
    Rosario-Jansen, Theresa
    Krasnow, Joel
    Hue, Trisha F.
    Sellmeyer, Deborah
    Eriksen, Erik Fink
    Cummings, Steven R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) : 1809 - 1822
  • [10] Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
    Black, Dennis M.
    Kelly, Michael P.
    Genant, Harry K.
    Palermo, Lisa
    Eastell, Richard
    Bucci-Rechtweg, Christina
    Cauley, Jane
    Leung, Ping Chung
    Boonen, Steven
    Santora, Arthur
    de Papp, Anne
    Bauer, Douglas C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (19) : 1761 - 1771